Zepbound achieved an average weight loss of 20.2% at 72 weeks in adults living with obesity without diabetes, compared with ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly ...

Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...